Cutaneous Oncology Program
Nationally recognized leader in skin cancer care, management and investigation.
Clinicians at BIDMC work together to evaluate and treat patients with complicated cutaneous cancers, such as melanoma, cutaneous lymphomas (specifically mycosis fungoides), and other skin malignancies. Their efforts have been instrumental in developing new therapies. In the Pigmented Lesion Clinic, physicians use sophisticated digital technology to monitor patients with multiple atypical moles who are at high risk for melanoma.
Active areas of investigation involve:
- melanoma prevention
- the genetics of melanoma in high-risk families
- adjuvant therapy in patients with high-risk melanomas
- cytokine and vaccine-based immunotherapy
- assessing and manipulating tumor-induced immune suppression
- several promising molecularly targeted therapies
- identification of factors associated with disease progression or predictive of response-to-therapy
Many of these activities are supported through the NCI-sponsored skin cancer SPORE grant through the DF/HCC.
